Patent applications published 17 March 2010
- A method for modulating the release rate of microencapsulated active ingredients
Endura; Sipcam 2161991*
- Alkoxylated asymmetric alkylamine surfactants as adjuvants
Akzo Nobel 2161992*
- Urotensin II receptor antagonists
Janssen Pharmaceutica 2161994*
- A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-B) indoles, its pharmacological compound and application method
Medivation neurology 2161995*
- Carboxamide heterocyclic CGRP receptor antagonists
Merck Sharp & Dohme 2161996*
- Tricyclic inhibitors of fatty acid amide hydrolase
Boger, Dale; The Scripps Research Institute 2161997*
- Novel methods
Intra-Cellular Therapies 2161998*
- Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes
VeroScience 2162003*
- Nucleic acid nanoparticles and uses therefor
Anterios 2162117*
- Porous microspheres and their use in therapy
King’s College London 2162118*
- Stable pharmaceutical formulation for a DPP-IV inhibitor
Phenomix Corp 2162119*
- Nanoparticles comprising a non-ionisable cellulosic polymer and an amphiphilic non-ionisable block copolymer
Bend Research 2162120*
- Method for coating surfaces with micro- and nanoparticles with the aid of plasma methods
Ernst-Moritz-Arndt-Universität Greifswald; Institut für Niedertemperatur-Plasmaphysik 2162121*
- Compsns for prevention or treatment of anorexia-cachexia syndrome and uses thereof
F.p.I Pharma 2162122*
- Honokiol analogues and their use in treating cancers
Arbiser, Jack 2162123*
- Neramexane for the treatment of nystagmus
Merz Pharma 2162124*
- Materials and methods for treating and diagnosis of disorders associated with oxidative stress
Pravda, Jay 2162125*
- Enteric coated soluble creatine and polyethylene glycol compsn for enhanced skeletal uptake of oral creatine
Phenolics 2162126*
- Compsn useful for the prevention of adverse effect due to the use of PPAR-gamma agonists
Sigma-Tau Industrie Farmaceutiche Riunite 2162127*
- Sesquiterpene formulations, kits and methods of use thereof
F.p.I Pharma 2162128*
- Use of HDAC inhibitors for the treatment of bone destruction
Novartis 2162129*
- Triazol compounds for treating biofilm formation
Novartis 2162130*
- Quinoline derivatives as P13 kinase inhibitors
GlaxoSmithKline 2162131*
- Heterocyclic kinase modulators
SGX Pharmaceuticals 2162132*
- Methods of reducing allergies caused by environmental allergens
Nestec 2162133*
- Carbostyril derivatives including cilostazol for treating fatty liver
Otsuka Pharmaceutical 2162134*
- Compsns, synthesis and methods of using quinoline based atypical antipsychotic
agents
Reviva Pharmaceuticals 2162135*
- Benzamide MGLUR5 positive allosteric modulators and methods of making and using the same
Vanderbilt University 2162136*
- Method of treating cognitive disorders by inhibition of GPR12
Helicon Therapeutics 2162137*
- Compsns useful for reducing nephrotoxicity and methods of use thereof
Verrow Pharmaceuticals 2162138*
- Curing accelerator and method of making
Adhezion Biomedical 2162139*
- Highly stable electrolytic water with reduced NMR half line width
Akuatech 2162140*
- Compsn for treating ischaemic limb disease comprising stem cells derived from adipose tissue
RNL Bio 2162141*
- Acellular tissue matrix compsns for tissue repair
Lifecell Corp 2162142*
- Mammalian milk microorganisms, compsns containing them and their use for the treatment of mastitis
Puleva Biotech 2162143*
- A novel reference plant, a method of its production, extracts obtained therefrom and their use
GW Pharma 2162144*
- Novel compounds and pharmaceutical preparations from Neobeguea spec
Dicotyledon 2162145*
- Use of transferrin for preparing pharmaceutical compsns useful for treating bacterial infections as coadjuvants in antibiotic therapy
Kedrion 2162146*
- Modified human factor VII/VIII and pharmaceutical compsn containing same
LFB Biotechnologies 2162147*
- System and method for sparql-query processing using parametrized-sparql-query in DBMS-based systems
GlaxoSmithKline Biologicals; Institut Pasteur; Vickles, Brenda 2162148*
- Vaccine for the prevention of breast cancer relapse
The Henry M Jackson Foundation for the Advancement of Military Medicine 2162149*
- Vaccine against Clostridium perfringens
University of Guelph 2162150*
- A live attenuated antigenically marked classical swine fever vaccine
The United States of America, as represented by the Secretary of Agriculture 2162151*
- Cripto binding molecules
Biogen Idec 2162152*
- Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
Novus International 2162153*
- Immunoxytes for cancer treatment in combination with chemotherapeutic agents
Philogen 2162156*
- Use of 3-alkanoyoxymethylcarbonyl nitroxide esters as oximetry probes for measurement of oxygen status in tissues
University of Maryland Biotechnology Institute; University of Maryland at Baltimore; University of New Mexico 2162157*
- Coated hyaluronic acid particles
Allergan 2162158*
- Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties
Abbott Cardiovascular Systems 2162159*
- Method and system for mitigating current concentration in electrokinetic drug delivery
Transport Pharmaceuticals 2162182*
- Electrophoretic transdermal application system
Acino; Friedrich-Alexander-Universität Erlangen-Nürnberg 2162183*
- Methods of restoration of erectile function
Wake Forest University Health Sciences 2162189*
- Biphenylcarboxamide derivatives as hedgehog pathway modulators
IRM LLC 2162190*
- Process of racemisation of optically active alpha aminoacetals
Clariant Speciality Fine Chemicals (France) 2162426*
- Benzamides useful as S1P receptor modulators
Novartis 2162427*
- Antiviral compounds
Gilead Science 2162431*
- Antiviral compounds
Gilead Science 2162432*
- 4’-substituted compounds having 5-HT6 receptor affinity
Memory Pharmaceuticals 2162433*
- Salts of perindopril
Krka Tovarna Zdravil 2162434*
- Ionic liquids as electrolytes
Invista Technologies 2162435*
- Novel case of renin inhibitors
Merck Frosst Canada 2162436*
- Enrofloxacin-hexahydrate
Bayer Animal Health 2162437*
- Process for the preparation of ivabradine hydrochloride and polymorph thereof
Ind-Swift Laboratories 2162438*
- Tricyclic inhibitors of hydroxysteroid dehydrogenases
Amgen 2162439*
- Process for preparing 2-amino-5-cyanobenzoic acid derivatives
EI du Pont de Nemours 2162440*
- 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation
Eldrug 2162441*
- Dual acting benzoimidazole antihypertensive agents
Theravance 2162442*
- Heteroarylamide-substituted pyrimidine derivatives for the treatment of neurodegenerative diseases
Sanofi-Aventis; Mitsubishi Tanabe Pharma 2162443*
- An improved process for erlotinib hydrochloride
Hetero Drugs 2162444*
- Heterobicyclic compounds as kinase inhibitors
Takeda Pharmaceutical 2162445*
- Isothiazole and pyrazole derivatives as fungicides
Syngenta Participations 2162448*
- Improved process for amorphous rabeprazole sodium
Hetero Drugs 2162449*
- ((Bicyclicheteroaryl) imidazol) methylheteroaryl compounds as adrenergic receptor agonists
Allergan 2162450*
- Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
Neurogen 2162451*
- Spirocyclopropyl piperidine derivatives
AstraZeneca 2162452*
- Crystalline form B of olmesartan medoxomil
Generics (UK) 2162453*
- Imidazopyridine kinase inhibitors
GlaxoSmithKline 2162454*
- Pyrollopyridine compounds, process for their preparation and their use as medicaments
Glaxo Group 2162455*
- Process for preparing the stable, amorphous calcium salt of (6S)-N-(5)-methyl-5,6,7,8-tetrahydrofolic acid
Cerbios-Pharma 2162456*
- Carbazolyl polymers for organic electronic devices
General Electric 2162457*
- Protein kinase-binding nucleosides and associated methods
Brigham Young University 2162458*
- Transcriptomic biomarkers for individual risk assessment in new onset heart failure
University of Miami 2162459*
- Vaccines against chlamydia infection
Emergent Product Development Gaitherburg 2162460*
- Targeted induction of aggregation of proteins with cross beta structures
VIB VZW 2162461*
- A CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide
Pharis Biotec 2162462*
- VEGF-D mutants and their use
Ark Therapeutics 2162463*
- Natriuretic fusion proteins
Boehringer Ingelheim International 2162464*
- Polypeptides, antibody variable domains and antagonists
Domantis 2162465*
- Polypeptides, antibody variable domains and antagonists
Domantis 2162466*
- Novel rabbit antibody humanisation methods and humanised rabbit antibodies
Alder Biopharmaceuticals 2162469*
- C38 antibodies and methods for the prevention and treatment of complement-associated disorders
Genentech 2162470*
- Compsns and methods for treating pancreatic tumours
Université de la Méditerranée; INSERM (Institut National de la Santé et de la Recherche Médicale); Innate Pharma 2162471*
- Immunoglobulin fusion proteins
Postech Academy-Industry Foundation; Genexine 2162472*